AUA 2018

AUA 2018: Treatment of Non-Obstructive Urolithiasis is Effective in Treatment of Recurrent Urinary Tract Infections

San Francisco, CA USA ( Deepak Agarwal, MD, a clinical urologist from the Mayo Clinic in Rochester Minnesota, presents his research on the treatment of non-obstructive urinary calculi to treat recurrent urinary tract infections (UTIs). Patients who present with these two conditions are particularly challenging patients to treat and are associated with a significant morbidity and cost. According to Dr. Agarwal, there has been growing evidence that the surgical removal of these non-obstructing stones may be beneficial to the treatment of recurrent UTIs. Additionally, it has been shown in previous research that kidney stones can be colonized with bacteria despite appropriate antibiotic administration. Therefore, Dr. Agarwal and his team sought to determine whether or not these procedures are effective.

AUA 2018: Estrogen Receptor β Promotes Renal Cell Carcinoma Progression via Regulating LncRNA HOTAIR-miR-138/200c/204/217 Associated CeRNA Network

San Francisco, CA USA ( relationship between the estrogen receptor and many known hormone-sensitive tumors has been identified, but the relationship of that and renal tumors has not been clearly observed. This clinical study presented by Jie Ding, MD, a urology specialist of the University of Rochester Medical Center, composed of the effect of over expressions and knockout of the estrogen receptor beta and the survival rate of patients with RCC. Although there was already identification between the regulatory relationship between the alpha and beta receptor,

AUA 2018: Use of Urinary Metabolomics to Identify High-Risk Clear Cell Renal Cell Carcinoma

San Francisco, CA USA ( Mohit Gupta, MD, a urologic oncologist at John Hopkins University of Medicine, presented a study regarding metabolomic markers that may identify and differentiate high-risk clear cell RCC from benign tumors. Dr. Gupta began the presentation by introducing the importance of metabolomics to identify discrepancies within current pathways known to urologic oncology. Although these pathways have been studied and used for different types of cancers, specific markers within urine of patients with ccRCC have not been clearly identified.

AUA 2018: The More You See, The More You Miss: Association Between PI-RADS Score of the Index Lesion and Multi-Focal, Clinically Significant Prostate Cancer

San Francisco, CA ( An extremely important consequence of our growing comfort with MRI-fusion targeted prostate biopsies is that systematic biopsies appear to be less important in some men. The results of the recent PRECISION trial, in fact, show that targeted biopsies alone may be a suitable way to detect clinically significant prostate cancer (csPC) in men undergoing diagnostic biopsies. The question lingers, though, about how much these targeted biopsies are potentially missing.

AUA 2018: Multi-Institutional External Validation of the EAU Guidelines for the Use of Staging mpMRI Prior to Radical Prostatectomy in Men with Intermediate and High-Risk Prostate Cancer

San Francisco, CA (  Current EAU guidelines advocate for the use of mpMRI for patients with high risk disease (defined as high risk on D’Amico criteria or >=ISUP Grade 3) for local staging purposes. These recommendations are based on evidence that has not previously been externally validated, though. The presenters, therefore, used a 4-institutional cohort of men in Europe to evaluate the utility of mpMRI for these high-risk men in a real-world setting.

AUA 2018: Association of Systematic Biopsy vs. Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsy with Prostate Cancer Upstaging at Radical Prostatectomy

San Francisco, CA (  Multiparametric prostate MRI (mpMRI) has clear utility for many aspects of prostate cancer diagnosis, staging, and preoperative planning. However, given that it is a relatively newly-adopted modality, little is known regarding how mpMRI might predict downstream outcomes for patients undergoing treatment for prostate cancer.

AUA 2018: Evaluation of Gallium-68 PSMA PET/CT Imaging in Individuals with Biochemical Recurrence Following Radical Prostatectomy

San Francisco, CA (  Ga-68 PSMA PET is growingly seen as one of the most important breakthroughs in prostate cancer imaging over the past decade. Its ability to detect metastatic disease that was previously invisible to conventional CT and bone scan imaging makes it a very attractive imaging modality for both clinical and research use.